Alemtuzumab pretreatment and tacrolimus monotherapy in living-donor liver and kidney transplantation

References

• Tan HP, Kaczorowski DJ, Basu A et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am. J. Transplant.6, 2409–2417 (2006).
   PubMed Web of Science ®Google Scholar
• Tan HP, Marsh W, Marcos A. Liver resection using a saline-linked radiofrequency dissecting sealer for transection of the liver. J. Am. Coll. Surg.201, 152 (2005).
   Google Scholar
• Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J. Am. Coll. Surg.200, 505–515 (2005).
   PubMed Web of Science ®Google Scholar
• Tan HP, Kaczorowski DJ, Basu A et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation78, 1683–1688 (2004).
   PubMed Web of Science ®Google Scholar
• Tan HP, Kaczorowski DJ, Basu A et al. Steroid-free tacrolimus monotherapy following pretransplant thymoglobulin or Campath and laparoscopy in living donor renal transplantation. Transpl. Proc.37, 4235–4240 (2005).
   PubMed Web of Science ®Google Scholar
• Shapiro R, Ellis D, Tan HP et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J. Pediatr.148, 813–818 (2006).
   PubMed Web of Science ®Google Scholar
• Shapiro R, Jordan ML, Basu A et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann. Surg.238, 520–525 (2003).
   PubMed Web of Science ®Google Scholar
• Basu A, Ramkumar M, Tan HP et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transpl. Proc.37, 923–926 (2005).
   PubMed Web of Science ®Google Scholar
• Hill P, Gagliardini E, Ruggenenti P, Remuzzi G. Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. Nephrol. Dial. Transplant.20, 1741–1744 (2005).
   PubMed Web of Science ®Google Scholar
• Knechtle SJ. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr. Transplant.8, 106–112 (2004).
   PubMed Web of Science ®Google Scholar
• Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation76(1), 120–129 (2003).
   PubMed Web of Science ®Google Scholar
• Knechtle SJ, Pirsch JD, H Fechner J Jr et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant.3, 722–730 (2003).
   PubMed Web of Science ®Google Scholar
• Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation – efficacy and safety at five years. Am. J. Transplant.5, 1347–1353 (2005).
   PubMed Web of Science ®Google Scholar
• Knechtle SJ, Fernandez LA, Pirsch JD et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery136, 754–760 (2004).
   PubMed Web of Science ®Google Scholar
• Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am. J. Transplant.5, 3009–3014 (2005).
   PubMed Web of Science ®Google Scholar
• Kaufman DB, Leventhal JR, Axelrod D et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction – long-term results. Am. J. Transplant.5, 2539–2548 (2005).
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation80, 457–465 (2005).
   PubMed Web of Science ®Google Scholar
• McCurry K, Iacano A, Zeevi A et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J. Thorac. Cardiovasc. Surg.130, 528–537 (2005).
   PubMed Web of Science ®Google Scholar
• Tzakis A, Kato T, Nishida S et al. Preliminary experience with Campath 1H (C1H) in intestinal and liver transplantation. Transplantation75, 1227 (2003).
   PubMed Web of Science ®Google Scholar
• Gruessner RWG, Kandaswamy R, Humar A et al. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation79(9), 1184 (2005).
   PubMed Web of Science ®Google Scholar
• Tryphonopoulos P, Madariaga JR, Kato T et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant. Proc.37, 1203 (2005).
   Google Scholar
• Starzl TE, Demetris AJ, Murase N et al. Cell migration, chimerism, and graft acceptance. Lancet339, 1579–1582 (1992).
   PubMed Web of Science ®Google Scholar
• Starzl TE, Demetris AJ, Trucco M et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology17, 1127–1152 (1993).
   PubMed Web of Science ®Google Scholar
• Abu-Elmagd K. Intestinal transplantation for short gut syndrome and gut failure: rewarding outcomes and current consensus. Gastroenterology130(2), 132–137 (2006).
   Google Scholar
• Thai NL, Khan A, Tom K et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: one and two-year outcomes. Transplantation82(12), 1621–1624 (2006).
   PubMed Web of Science ®Google Scholar